NASDAQ:NKTR
Nektar Therapeutics Stock News
$1.76
-0.0450 (-2.50%)
At Close: May 17, 2024
Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates
10:35pm, Monday, 28'th Feb 2022 Zacks Investment Research
Nektar (NKTR) delivered earnings and revenue surprises of 2.47% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics GAAP EPS of -$0.79 beats by $0.02, revenue of $25M misses by $0.33M
09:21pm, Monday, 28'th Feb 2022 Seeking Alpha
Nektar Therapeutics press release (NKTR): Q4 GAAP EPS of -$0.79 beats by $0.02.Revenue of $25M (+6.6% Y/Y) misses by $0.33M.Shares -0.88%.Cash and investments in marketable…
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
09:15pm, Monday, 28'th Feb 2022 PR Newswire
SAN FRANCISCO, Feb. 28, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Cash and investments in marketable securities at December 31, 2021 were approximately $0.8 billion as compared to…
Nektar Therapeutics' (NKTR) CEO Howard Robin on Q4 2021 Results - Earnings Call Transcript
08:07pm, Monday, 28'th Feb 2022
Nektar Therapeutics' (NKTR) CEO Howard Robin on Q4 2021 Results - Earnings Call Transcript
Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates
07:08pm, Monday, 28'th Feb 2022
Nektar (NKTR) delivered earnings and revenue surprises of 2.47% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics Q4 2021 Earnings Preview (NASDAQ:NKTR)
10:35pm, Sunday, 27'th Feb 2022 Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.80 and the consensus…
Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight
06:00pm, Monday, 21'st Feb 2022 Benzinga
Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Toll-Like Receptor Agonist treatment scenario include InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics, Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and many others.
Indices - Nektar Therapeutics Expected to Post Earnings of -$0.81 Per Share
07:21am, Sunday, 20'th Feb 2022 Business Mag
Analysts forecast that Nektar Therapeutics will post earnings per share of for the current quarter, according to Zacks Investment Research. Five analysts have made estimates
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets
11:00pm, Thursday, 17'th Feb 2022 PR Newswire
/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday,…
Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for
08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, Feb. 17, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday, February 28, 2
Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight
06:00pm, Wednesday, 09'th Feb 2022 Benzinga
Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.
12 biotech stocks to consider buying now as prospects for the sector brighten this year
02:01pm, Monday, 07'th Feb 2022 MarketWatch
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.
Is the Options Market Predicting a Spike in Nektar Therapeutics (NKTR) Stock?
01:56pm, Friday, 31'st Dec 2021 Zacks Investment Research
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Nektar Therapeutics (NKTR) Stock?
09:58am, Friday, 31'st Dec 2021
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.